Journal Publication

Incretin obesity drugs spare muscle function despite mild lean-mass loss, study finds

A mouse-and-human analysis finds weight loss from incretin-based therapies comes mostly from fat and liver mass, with muscle-to-bodyweight ratio and strength relative to weight improving rather than declining.

By AppliedXLAugust 6, 2025

Executive Summary

Researchers examined whether the rapid weight loss produced by incretin-based anti-obesity medications comes at a disproportionate cost to skeletal muscle, a concern raised by prior clinical observations of lean-mass loss during treatment.
In obese mice, incretin therapy reduced fat and liver mass far more than muscle, so the muscle-to-bodyweight ratio and running performance improved even as absolute muscle mass and strength fell slightly.
Patients on these medications lost body weight with only a mild drop in absolute lean mass, no decline in muscle strength as measured by maximum voluntary contraction, and an improved lean-mass-to-weight ratio.
The findings weigh against the idea that incretin-driven weight loss preferentially wastes muscle, reframing the sarcopenic-obesity concern as a question of relative proportion rather than a disproportionate muscle-specific loss.

The question

Incretin-based anti-obesity medications have become the first widely available non-surgical option for the roughly 936 million people worldwide living with obesity, cited in the study as the scale of the population these drugs target. But clinical observations that patients lose lean body mass alongside fat during treatment raised concern that the drugs could accelerate sarcopenic obesity, a decline in muscle mass and function layered onto obesity itself. Muscle mass and function are not routinely measured in obesity trials, so the study authors set out to generate original data on the question, combining mouse experiments with a proof-of-concept clinical trial. Pharmacological

How it was done

The work paired diet-induced obese (DIO) mice treated with incretin-based therapies against comparator groups, including a pair-fed, calorie-matched arm during a period of imposed immobilization designed to provoke muscle wasting, with a human proof-of-concept clinical trial layered on top. Outcomes measured in mice included absolute and relative (to bodyweight) muscle mass, muscle strength, liver and fat mass, and running performance; the human arm measured bodyweight, absolute and relative lean body mass, and muscle function via maximum voluntary contraction (MVC). Pharmacological

The mouse result

In DIO mice, incretin-based therapy produced a decrease in fat mass alongside a small decrease in lean body mass, with the drop in liver mass exceeding the change in muscle mass. Absolute muscle mass and strength both fell mildly, but muscle mass and strength measured relative to bodyweight improved, and running performance improved alongside that relative preservation of muscle. During an imposed immobilization period designed to maximize muscle wasting, mice on incretin therapy lost no more muscle than calorie-matched, pair-fed controls, indicating the drug itself was not compounding muscle loss beyond what caloric restriction alone would produce. Pharmacological

The human result

In the clinical proof-of-concept trial, patients on anti-obesity medications lost bodyweight with a mild decrease in absolute lean body mass, but their lean-mass-to-bodyweight ratio improved. Muscle function, measured by maximum voluntary contraction, did not decline. Taken together with the mouse data, the pattern across both species is consistent: absolute muscle mass and strength decline modestly during incretin-driven weight loss, but that decline is outweighed by larger reductions in fat and liver mass, so the proportion of the body made up of muscle, and functional measures like strength and mobility, both improve. Pharmacological

What this changes

The results speak to a live concern among clinicians managing obesity pharmacotherapy: that dramatic weight loss achieved with incretin-based drugs might come predominantly from lean tissue rather than fat, undermining the functional benefit of treatment. The mouse and human data instead show muscle loss is proportionally smaller than fat and liver loss, and that functional measures of strength and mobility hold up or improve during treatment. That distinction, between absolute lean-mass decline and relative muscle preservation, is the throughline connecting the preclinical immobilization experiment to the human MVC result. Pharmacological

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.